Overview
Megacystis-microcolon-intestinal hypoperistalsis syndrome (MMIHS), also known as Berdon syndrome, is a severe congenital disorder affecting the smooth muscle function of the bladder and intestines. It is characterized by three cardinal features: a massively enlarged, non-obstructed urinary bladder (megacystis), an abnormally small colon (microcolon), and decreased or absent intestinal peristalsis (the wave-like muscle contractions that move food through the digestive tract). The condition is typically detected prenatally or at birth, often presenting with abdominal distension, failure to pass meconium, and bilious vomiting in the neonatal period. Hydronephrosis (swelling of the kidneys) is frequently observed due to impaired bladder emptying. MMIHS primarily affects the gastrointestinal and urinary systems. The underlying pathology involves dysfunction of visceral smooth muscle cells, and mutations in the ACTG2 gene (encoding gamma-2 smooth muscle actin) have been identified as a major cause. Mutations in MYH11 and LMOD1 have also been implicated in some cases. The condition leads to functional intestinal obstruction, making affected individuals unable to tolerate enteral feeding. Most patients require long-term total parenteral nutrition (TPN) for survival, and some may be considered for intestinal or multivisceral transplantation. The prognosis for MMIHS remains poor despite advances in supportive care. Complications of long-term TPN, including liver disease and recurrent central line infections, contribute significantly to morbidity and mortality. Many affected infants do not survive beyond the first year of life, although improved nutritional support and transplantation have extended survival in some cases. There is currently no curative treatment, and management is primarily supportive, focusing on nutritional optimization, urinary drainage, and prevention of complications.
Also known as:
Clinical phenotype terms— hover any for plain English:
Variable
Can be inherited in different ways depending on the underlying gene
Neonatal
Begins at or shortly after birth (first 4 weeks)
Treatments
No FDA-approved treatments are currently listed for Megacystis-microcolon-intestinal hypoperistalsis syndrome.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Megacystis-microcolon-intestinal hypoperistalsis syndrome at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Megacystis-microcolon-intestinal hypoperistalsis syndrome.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Megacystis-microcolon-intestinal hypoperistalsis syndrome.
Community
No community posts yet. Be the first to share your experience with Megacystis-microcolon-intestinal hypoperistalsis syndrome.
Start the conversation →Latest news about Megacystis-microcolon-intestinal hypoperistalsis syndrome
No recent news articles for Megacystis-microcolon-intestinal hypoperistalsis syndrome.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Megacystis-microcolon-intestinal hypoperistalsis syndrome
What is Megacystis-microcolon-intestinal hypoperistalsis syndrome?
Megacystis-microcolon-intestinal hypoperistalsis syndrome (MMIHS), also known as Berdon syndrome, is a severe congenital disorder affecting the smooth muscle function of the bladder and intestines. It is characterized by three cardinal features: a massively enlarged, non-obstructed urinary bladder (megacystis), an abnormally small colon (microcolon), and decreased or absent intestinal peristalsis (the wave-like muscle contractions that move food through the digestive tract). The condition is typically detected prenatally or at birth, often presenting with abdominal distension, failure to pass
At what age does Megacystis-microcolon-intestinal hypoperistalsis syndrome typically begin?
Typical onset of Megacystis-microcolon-intestinal hypoperistalsis syndrome is neonatal. Age of onset can vary across affected individuals.